f1
Correspondence: Eugene Braunwald, M.D., Brigham and Women's Hospital, 75 Francis Street, Boston MA 02115, U.S.A.

References

1
Chidsey
CA
, Harrison DC, Braunwald E. Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure.
N Engl J Med
 .
1962
;
267
:
650
–654
2
Braunwald
E
, Chidsey CA. The adrenergic nervous system in the control of the normal and failing heart.
Proc Roy Soc Med
 .
1965
;
58
:
1063
–1066
3
Chidsey
CA
, Braunwald E, Morrow AG. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure.
Am J Med
 .
1965
;
39
:
442
–451
4
Chidsey
CA
, Braunwald E, Morrow AG, Mason DT. Myocardial norepinephrine concentration in man. Effects of reserpine and of congestive heart failure.
N Engl J Med
 .
1963
;
269
:
653
–658
5
Chidsey
CA
, Sonnenblick EH, Morrow AG, Braunwald E. Norepinephrine stores and contractile force of papillary muscle from the failing human heart.
Circulation
 .
1966
;
33
:
43
–51
6
Chidsey
CA
, Kaiser GA, Sonnenblick EH, Spann JF, Braunwald E. Cardiac norepinephrine stores in experimental heart failure in the dog.
J Clin Invest
 .
1964
;
43
:
2386
–2393
7
Covell
JW
, Chidsey CA, Braunwald E. Reduction of the cardiac response to postganglionic sympathetic nerve stimulation in experimental heart failure.
Circ Res
 .
1966
;
19
:
51
–56
8
Epstein
SE
, Braunwald E. Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications.
N Engl J Med
 .
1966
;
275
:
1106
–1112
9
Leimbach
WN
Jr
, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure.
Circulation
 .
1986
;
73
:
913
–919
10
Cohn
JN
, Olivari MT, Garberg V. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.
N Engl J Med
 .
1984
;
311
:
819
–823
11
Packer
M
, Bristow MR, Cohn JN. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure.
N Engl J Med
 .
1996
;
334
:
1349
–1355
12
Lancet
 .
1999
;
353
:
9
–13
13
Lancet
 .
1999
;
353
:
2001
–2007
14
Pfeffer
JM
, Pfeffer MA, Mirsky E, Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat.
Proc Nat Acad Sci
 .
1982
;
79
:
3310
–3314
15
Pfeffer
JM
, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat.
Circ Res
 .
1985
;
57
:
84
–95
16
Pfeffer
MA
, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effects of captopril on progressive ventricular dilatation after anterior myocardial infarction.
N Engl J Med
 .
1988
;
319
:
80
–86
17
Pfeffer
MA
, Braunwald E, Moye LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement (SAVE) Trial.
N Engl J Med
 .
1992
;
327
:
669
–677
18
Circulation
 .
1998
;
97
:
2202
–2212
19
Flather
M
, Yusuf S, Kober L. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients.
Lancet
 .
2000
;
355
:
1575
–1581
20
Hirsch
AT
, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure.
Circ Res
 . ;
69
:
475
–482
21
Rutherford
JD
, Pfeffer MA, Moye L. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial.
Circulation
 .
1994
;
90
:
1731
–1738
22
N Engl J Med
 .
2000
;
342
:
145
–153
23
Pfeffer
MA
, Domanski M, Rosenberg Y. Prevention of events with angiotensin converting enzyme inhibition: The PEACE Study design.
Am J Cardiol
 .
1998
;
82
:
25H
–30H
24
Grassi
G
, Cattaneo BM, Seravalle G. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure.
Circulation
 .
1997
;
96
:
1173
–1179
25
Circulation
 .
2000
;
101
:
378
–384
26
Francis
GS
, Cohn JN, Johnson G. Plasma norepinephrine, plasma renin activity, and congestive heart failure: Relations to survival and the effects of therapy in V-HeFT.
Circulation
 .
1993
;
87
:
VI-40
–VI-48
27
MacFadyen
RJ
, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability, and reduces early morning rise in heart rate in heart failure patients.
Cardiovasc Res
 .
1997
;
35
:
30
–34
28
Pitt
B
, Zannad F, Remme WJ. The effect of spironolactone on morbidity and mortality in patients with severe heart failure.
N Engl J Med
 .
1999
;
341
:
709
–717
29
Pacher
R
, Stanek B, Hulsmann M. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure.
J Am Coll Cardiol
 .
1996
;
27
:
633
–641
30
Mulder
P
, Richard V, Derumeaux G. Role of endogenous endothelin in chronic heart failure: effect of longterm treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
Circulation
 .
1997
;
96
:
1976
–1982
31
Luscher
TF
, Barton M. Endothelins and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs.
Circulation
 .
2000
;
102
:
2434
–2440
32
Rouleau
JL
, Pfeffer MA, Steward DJ. Comparison of vasopeptidase inhibitor, omapatrilat, and lisnopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
Lancet
 .
2000
;
356
:
615
–620
33
Dao, W, Krishnaswamy, P, Kazanegra, R, Utility of B-type natriuretic peptide (BNP) in the diagnosis of CHF in an urgent care setting, J Am Coll Cardiol
34
Colucci
WS
, Elkayam U, Horton DP. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure.
N Engl J Med
 .
2000
;
343
:
246
–253
35
Levine
B
, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.
N Engl J Med
 .
1990
;
223
:
236
–241
36
Torre-Amione
G
, Kapadia S, Lee J. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart.
Circulation
 .
1996
;
93
:
704
–711
37
Braunwald
E
, Bristow MR. Congestive Heart Failure: Fifty years of progress.
Circulation
 .
2000
;
102
:
IV14
–IV23
38
Bryant
D
, Becker L, Richardson J. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α.
Circulation
 .
1998
;
97
:
1375
–1381
39
Bozkurt
B
, Kribbs S, Clubb M Jr. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats.
Circulation
 .
1998
;
97
:
1382
–1391
40
Deswal
A
, Bozkurt B, Seta Y. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, Entanercept) in patients with advanced heart failure.
Circulation
 .
1999
;
99
:
3224
–3226
41
Guillermo
T-A
, Stetson ST, Youker KA. Decreased expression of tumor necrosis factor-α in failing human myocardium after mechanical circulatory support. A potential mechanism for cardiac recovery.
Circulation
 .
1999
;
100
:
1189
–1193
42
Bristow
MR
, Ginsburg R, Minobe WA. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts.
N Engl J Med
 .
1982
;
307
:
205
–211
43
Waagstein
F
, Hjalmarson A, Varnauskas E. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.
Br Heart J
 .
1975
;
7
:
1022
–1036
44
Spann
JF
Jr
, Buccino RA, Sonnenblick EH, Braunwald E. Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure.
Circ Res
 .
1967
;
21
:
341
–354
45
Koide
M
, Nagatsu M, Zile MR. Premorbid determinants of left ventricular dysfunction in a novel model of gradually induced pressure overload in the adult canine.
Circulation
 .
1997
;
95
:
1601
–1610
46
Miyata
S
, Minobe WA, Bristow MR, Leinwand LA. Myosin heavy chain isoform expression in the failing and non-failing human heart.
Circ Res
 .
2000
;
86
:
386
–390
47
Heerdt
PM
, Holmes JW, Cai B. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure.
Circulation
 .
2000
;:
713
–719
48
Schwinger
RHG
, Munch G, Bolck B. Reduced Ca2+-sensitivity of SERCA 2a in failing human myocardium due to reduced serine16 phospholamban phosphorylation.
J Mol Cell Cardiol
 .
1999
;
31
:
479
–491
49
Hasenfuss
G
, Schillinger W, Lehnart SE. Relationship between Na+-Ca2+exchanger protein levels and diastolic dysfunction of failing human myocardium.
Circulation
 .
1999
;
99
:
641
–648
50
Sabbah
HN
. Apoptotic cell death in heart failure.
Cardiovasc Res
 .
2000
;
45
:
704
–712
51
Hein
S
, Kistin S, Heling A, Maeno Y, Schaper J. The role of the cytoskeleton in heart failure.
Cardiovasc Res
 .
2000
;
45
:
272
–278
52
Weber
KT
. The heart's extracellular matrix.
Cardiovasc Res
 .
2000
;
46
:
211
–355
53
Li
YY
, Feldman AM, Sun Y, McTiernan DF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart.
Circulation
 .
1998
;
98
:
1728
–1734
54
Zannad
F
, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure.
Circulation
 .
2000
;
102
:
2700
–2706
55
Pool
PE
, Spann JF Jr, Buccino RA, Sonnenblick EH, Braunwald E. Myocardial high energy phosphate stores in cardiac hypertrophy and heart failure.
Circ Res
 .
1967
;
21
:
365
–373
56
Coleman
HN
, Taylor RR, Pool PE. Congestive heart failure following chronic tachycardia.
Am Heart J
 .
1971
;
81
:
790
–798
57
Shen
W
, Asai K, Uechi M. Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs. A compensatory role for the parallel loss of creatine.
Circulation
 .
1999
;
100
:
2113
–2118
58
Conway
MA
, Bottomley PA, Ouwerkerk R. Mitral regurgitation: impaired systolic function, eccentric hypertrophy, and increased severity are linked to low phosphocreatine/ATP ratios in humans.
Circulation
 .
1998
;
97
:
1716
–1723
59
Neubauer
S
, Horn M, Naumann A. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.
Circulation
 .
1997
;
96
:
2190
–2196
60
Braunwald
E
, Kloner RA. The stunned myocardium: Prolonged, postischemic ventricular dysfunction.
Circulation
 .
1982
;
66
:
1146
–1149
61
Rahimtoola
SH
. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina.
Circulation
 .
1985
;
72
:
V-123
–V-35
62
Braunwald
E
, Rutherford JD. Reversible ischemic left ventricular dysfunction: Evidence for the “hibernating myocardium”.
J Am Coll Cardiol
 .
1986
;
8
:
1467
–1470
63
Kloner
RA
, Bolli R, Marban E, Reinlib L, Braunwald E. Medical and cellular implications of stunning, hibernation, and preconditioning: An NHLBI Workshop.
Circulation
 .
1998
;
97
:
1848
–1867
64
Pagley
PR
, Beller GA, Watson DD. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy residual myocardial viability.
Circulation
 .
1997
;
96
:
793
–800
65
2001 Heart and Stroke Statistical Update
This content is only available as a PDF.

Comments

0 Comments